Biosion, In Global For Global, antibody-drug conjugate, bosakitug TSLP, SynTracer+Flexibody+H3

English

WELCOME TO BIOSION

Biosion is a global biotechnology company that is currently in the clinical stage.

Biosion is a global clinical-stage biotechnology company focused on developing innovative antibody-based therapies to improve outcomes for patients with immune and oncologic diseases. Leveraging its proprietary technologies such as the H³ antibody discovery platform, SynTracer® HT endocytosis platform, and Flexibody® bispecific platform, Biosion creates highly differentiated medicines to address significant unmet medical needs worldwide.

PARTNERING

In Global For Global

Empower our partners, unite our might, Accelerate innovation for global sight.

NEWS

News and Information

Spot the chance with global eyes, Meet unmet needs where healing lies.

Professional quality

2026-06-03

Biosion's Partner Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052

2026-06-03

Biosion's Partner Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052

Biosion's Partner Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052Release time:2025-06-26 11:05:00Nanjing, China, Newark, U.S.A June. 23, 2025-Biosion, a global, clinical-stage biotechnology company, announced that its partner, Aclaris Therapeutics, Inc.

2025-04-11

Biosion to Present Preclinical Data for Novel ADC Candidate at AACR Annual Meeting

2025-04-11

Biosion to Present Preclinical Data for Novel ADC Candidate at AACR Annual Meeting

NANJING, China and NEWARK, Del., April 11, 2025-Biosion, Inc. , a global, clinical-stage biotechnology company, today announced that preclinical data for BSI-721, a novel antibody-drug conjugate (ADC) targeting CDH17, will be presented at the upcoming American Association for Cancer Research (AAC

2025-04-27

Biosion's Partner Aclaris Therapeutics Announces FDA Clearance of IND Application for ATI-052, a Novel Bispecific Anti-TSLP/IL-4R Investigational Antibody

2025-04-27

Biosion's Partner Aclaris Therapeutics Announces FDA Clearance of IND Application for ATI-052, a Novel Bispecific Anti-TSLP/IL-4R Investigational Antibody

Newark, DE, U.S. and Nanjing, China, Apr. 27, 2025-Biosion, a global clinical-stage biotechnology company, announced that its partner, Aclaris Therapeutics, Inc. (NASDAQ: ACRS), has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) applicat

Find us in China, Hong Kong SAR, the United States & Australia

Quick Links